X @Bloomberg
Bloomberg·2026-07-31 05:40
Apnimed, a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US IPO, priced at the top of a marketed range. https://t.co/qubqf8kuAy ...
Apnimed, a late-stage drug developer focused on sleep apnea, raised $192 million in an upsized US IPO, priced at the top of a marketed range. https://t.co/qubqf8kuAy ...